Neutralizing monoclonal antibodies against SARS-CoV-2 for COVID-19 pneumonia in a rituximab treated patient with systemic sclerosis—A case report and literature review

Patients with immune-mediated diseases (IMID) such as systemic sclerosis (SSc), who are treated with B cell depleting treatments, are at risk for developing severe COVID-19 due to inadequate humoral immune response. During B cell depletion, therapeutic substitution of neutralizing monoclonal antibod...

Descripción completa

Detalles Bibliográficos
Autores principales: Yalcin Mutlu, Melek, Taubmann, Jule, Wacker, Jochen, Tascilar, Koray, Fagni, Filippo, Gerner, Maximilian, Klett, Daniel, Schett, Georg, Manger, Bernhard, Simon, David
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Medicine
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381861/
https://www.ncbi.nlm.nih.gov/pubmed/35991632
http://dx.doi.org/10.3389/fmed.2022.934169

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9381861/
https://www.ncbi.nlm.nih.gov/pubmed/35991632
http://dx.doi.org/10.3389/fmed.2022.934169

Ejemplares similares